Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

First-in-class BTK degrader, NX-5948, Granted ODD for WM and assigned nonproprietary name “bexobrutideg” in newly named degrader class of drugs
January 13, 2025 07:00 ET | Source: Amphista Therapeutics

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer Appointment supports the Company’s ambitions to advance its portfolio of next generation Targeted Glue™ protein degrader...
December 09, 2024 18:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patients with at least two disease assessments Treatment...
November 05, 2024 09:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
October 21, 2024 16:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Presentations will summarize new preclinical data from brain-penetrant, pan-mutant B-Raf degrader program and recent clinical data from NX-5948 BTK degrader program Members of the Nurix management...
June 16, 2024 05:30 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
April 09, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within...
March 25, 2024 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer Cancer Grand Challenges is an initiative funded by Cancer Research UK SAN...